Actively Recruiting
Study of MG-K10 Humanized Monoclonal Antibody Injection Compared to Placebo for Treating Seasonal Allergic Rhinitis in Adults Aged 18 to 75
Led by Shanghai Mabgeek Biotech.Co.Ltd · Updated on 2025-04-18
160
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MG-K10 humanized monoclonal antibody injection in a multicenter, randomized, double-blind, placebo-controlled Phase IIIII seamless clinical study for people with seasonal allergic rhinitis. The study aims to assess the drugs effectiveness, safety, how it moves through and acts in the body, and its potential to trigger immune responses. Around 120 patients in stage II and 106 patients in stage III with seasonal allergic rhinitis are included, all receiving a single dose. Participants receive either MG-K10 or a placebo as a single dose during the study. The study includes a screening period lasting one week, a four-week double-blind treatment period, and a two-week safety follow-up. The design ensures patients and researchers do not know which treatment is given during the treatment phase to fairly compare outcomes. During the study, patients have symptom scores recorded and monitored to evaluate changes in nasal symptoms. Researchers will assess the primary outcome of change in mean reflective total nasal symptom score rTNSS after two weeks, along with secondary outcomes at two and four weeks. Patients are followed closely for safety during and after treatment, with a total observation period of seven weeks from screening through follow-up.
CONDITIONS
Brief Title
Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis
Research Team
L
lipeng liu, bachelor
C
chao deng, bachelor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here